ABSTRACT
The novel coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The immune response to SARS-CoV-2 can play an important role in disease pathogenesis and clinical manifestations. Considering the antiviral, immuno-modulatory, anxiolytic, antiinflammatory and antioxidant properties, this open labelled, controlled, interventional, prophylactic study was conducted on individuals at risk in containment zones of different cities of India, viz., Lucknow, Aligarh, New Delhi, Srinagar, Mumbai and Bengaluru. The study focuses on number of patients turning COVID-19 positive, change in ISQ and WHOQOL-BREF scales in both the groups. Apparently, healthy individuals at risk in containment zones were divided into intervention and control groups. The intervention group was further divided into two subgroups. The first subgroup received Unani regimen- I including Unani Joshanda with Khamira Marwareed (KM), the second subgroup received Unani regimen- II including Unani Joshanda with Tiryaq Arba (TA). The control group did not receive any intervention. The duration of intervention was 20 days;follow ups were planned on day 10, day 20 and day 35. A total number of 33021 participants were enrolled in the study, of which 30,931 participants completed the study. It was observed that individuals receiving Unani regimen-I demonstrated lower risk of developing COVID-19 by 74% and those receiving Unani regimen-II by 62% in comparison to the control group. Interventional groups showed highly significant (p<0.001) effect on the quality of life.
ABSTRACT
Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative. Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management. Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14.This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003). Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group.